Discovery and clinical introduction of first-in-class imipridone ONC201

ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC2...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342060/
https://ncbi.nlm.nih.gov/pubmed/27602582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11814
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares